Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: Phase 3, randomized, placebo-controlled trial

Annals of Allergy, Asthma and Immunology

Volumn 112, Issue 2, 2014, Pages

  Riedl, Marc A ^a   Bernstein, Jonathan A ^b   Li, Henry ^c   Reshef, Avner ^d   Lumry, William ^e   Moldovan, Dumitru ^f   Farkas, Henriette ^g   Levy, Robyn ^h   Baker, James ⁱ   Hardiman, Yun ^j   Totoritis, Mark C ^j   Relan, Anurag ^k   Cicardi, Marco ^l  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c Institute for Asthma and Allergy   (United States)

^d SHEBA MEDICAL CENTER   (Israel)

^e AARA Research Center   (United States)

^f UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^g SEMMELWEIS UNIVERSITY   (Hungary)

^h Family Allergy and Asthma Center   (United States)

ⁱ Baker Asthma Allergy and Dermatology   (United States)

^j Santarus Inc   (United States)

^k Pharming Group NV   (Netherlands)

^l UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; D DIMER; PLACEBO;

ADOLESCENT; ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; BACKACHE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; LIPOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINUS CONGESTION; SKIN BURNING SENSATION; SNEEZING; TREATMENT DURATION; TREATMENT OUTCOME; VASOMOTOR RHINITIS;

ADOLESCENT; ADULT; AGED; ANGIOEDEMAS, HEREDITARY; ANIMALS; ANIMALS, GENETICALLY MODIFIED; COMPLEMENT C1 INACTIVATOR PROTEINS; COMPLEMENT INACTIVATING AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; QUESTIONNAIRES; RABBITS; RECOMBINANT PROTEINS; VISUAL ANALOG SCALE; YOUNG ADULT;

EID: 84893684243     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/j.anai.2013.12.004     Document Type: Article

References (29)

1. B.L. Zuraw Clinical practice. Hereditary angioedema N Engl J Med 359 2008 1027 1036
2. Cinryze (C1 esterase inhibitor [human]). Package insert. Available at: http://www.viropharma.com/products/cinryze/cinryze%20pi.aspx. Accessed June 4, 2013.
3. Berinert (C1 esterase inhibitor [human]). Package insert. Available at: http://druginserts.com/lib/other/meds/berinert. Accessed June 4, 2013.
4. P.K. Gandhi, W.M. Gentry, and M.B. Bottorff Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database Pharmacotherapy 32 2012 902 909
5. Viropharma, Inc. United States Securities and Exchange Commission Form 10-Q Quarterly report pursuant to sections 13 or 15(d) of the Securities and Exchange Act of 1934; filed on 10/28/2009; filed period 9/30/2009. Available at: http://apps.shareholder.com/sec/viewerContent.aspx?companyid=ABEA- 4ZUL1I&docid=6574386. Accessed June 4, 2013.
6. A. Boulis, S. Goold, and P.A. Ubel Responding to the immunoglobulin shortage: a case study J Health Polit Policy Law 27 2002 977 999
7. H.A. Van Veen, J. Koiter, and C.J. Vogelezang et al. Characterization of recombinant human C1 inhibitor secreted in milk of transgenic rabbits J Biotechnol 162 2012 319 326
8. B. Zuraw, M. Cicardi, and R.J. Levy et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema J Allergy Clin Immunol 126 2010 821 827.e14
9. D. Moldovan, A. Reshef, and J. Fabiani et al. Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study Clin Exp Allergy 42 2012 929 935
10. M.A. Riedl, R.J. Levy, and D. Suez et al. Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study Ann Allergy Asthma Immunol 110 2013 295 299
11. C. Farell, S. Hayes, A. Relan, E.S. van Amersfoort, R. Pijpstra, and C.E. Hack Population pharmacokinetics of recombinant human C1-inhibitor in patients with hereditary angioedema Br J Clin Pharmacol 76 2013 897 907
12. A. Reshef, D. Moldovan, and K. Obtulowicz et al. Recombinant human C1 inhibitor for the prophylaxis of hereditary angioedema attacks: a pilot study Allergy 68 2013 118 124
13. O.G. Maksimenko, A.V. Deykin, Y.M. Khodarovich, and P.G. Georgiev Use of transgenic animals in biotechnology: prospects and problems Acta Naturae 5 2013 33 46
14. M. Cugno, J.H. Nuijens, and C.E. Hack et al. Plasma levels of C1-inhibitor complexes and cleaved C1-inhibitor in patients with hereditary angioneurotic edema J Clin Invest 85 1990 1215 1220
15. C.E. Hack, A. Relan, E.S. van Amersfoort, and M. Cicardi Target levels of functional C1-inhibitor in hereditary angioedema Allergy 67 2012 123 130
16. T.J. Craig, R.J. Levy, and R.L. Wasserman et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks J Allergy Clin Immunol 124 2009 801 808
17. B.L. Zuraw, P. Busse, and M. White et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema N Engl J Med 363 2010 513 522
18. M. Kunschak, W. Engl, and F. Maritsch et al. A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema Transfusion 38 1998 540 549
19. C.V. McMillan, J. Speight, A. Relan, L. Bellizzi, G. Haase, and M. Cicardi Content validity of visual analog scales to assess symptom severity of acute angioedema attacks in adults with hereditary angioedema: an interview study Patient 5 2012 113 126
20. M. Cugno, A. Zanichelli, A.G. Bellatorre, S. Griffini, and M. Cicardi Plasma biomarkers of acute attacks in patients with angioedema due to C1-inhibitor deficiency Allergy 64 2009 254 257
21. T. Bowen, M. Cicardi, and H. Farkas et al. 2010 International consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema Allergy Asthma Clin Immunol 6 2010 24 36
22. T. Craig, E. Aygören-Pürsün, and K. Bork et al. WAO guideline for the management of hereditary angioedema World Allergy Organ J 5 2012 182 199
23. M. Cicardi, K. Bork, and T. Caballero et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an international working group Allergy 67 2012 147 157
24. W. Aberer, T.K. Hoffmann, and M. Wiednig et al. A study of the self-administration of icatibant for acute attacks of hereditary angioedema (HAE) Ann Allergy Asthma Immunol 105 2010 A92
25. W.R. Lumry, H.H. Li, and R.J. Levy et al. Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial Ann Allergy Asthma Immunol 107 2011 529 537
26. M. Cicardi, A. Banerji, and F. Bracho et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema N Engl J Med 363 2010 532 541
27. Kalbitor (ecallantide) clinical briefing document. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM193572.pdf. Accessed June 4, 2013.
28. Firazyr (icatibant) clinical briefing document. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM260020.pdf. Accessed June 4, 2013.
29. C.E. Hack, M. Mannesse, A. Baboeram, B. Oortwijn, and A. Relan Immunogenicity assessment of recombinant human C1-inhibitor: an integrated analysis of clinical studies Biodrugs 26 2012 303 313